Abstract
Purpose Respiratory rate is an important physiological parameter whose abnormality could be, in the presence of other suggestive symptoms, supportive of a diagnose of various serious illnesses. Photoplethysmography (PPG) in wearable sensors potentially plays an important role in early disease detection by making respiratory rate measurements more accessible. We investigated the accuracy of a new non-invasive, continuous, wrist-worn and wireless monitoring PPG device (Corsano CardioWatch 287) in measuring respiratory rate (RR) and heart rate (HR) at rest.
Methods Subjects with and without diagnosed Obstructive Sleep Apnea (OSA) underwent simultaneous, continuous PPG and home sleep apnea testing (HSAT) for one night. We assessed the PPG sensor’s measurement accuracy by calculating root-mean-square accuracy (Arms) and by performing Bland Altman and correlation analysis. Subgroups were defined based on skin type, hair density, age, BMI, gender and OSA severity.
Results In 26 participants a total of 31083 RR and 38693 HR measurement pairs were obtained. For RR measurements, Arms was 0.60 breaths per minute (brpm). Correlation was high (r = 0.964 (95%CI 0.963 - 0.965)) and 95% Limits of Agreement (LoA) were −1.28 to 1.71 brpm (mean bias −0.14 brpm). For HR measurements, Arms was 0.95 beats per minute (bpm). Correlation was similarly high (r = 0.996 (95%CI 0.996 - 0.996) and 95% LoA were – 2.09 to 1.17 bpm (mean bias −0.46 bpm). Results were comparable across all subgroups, without significant difference in RR accuracy between subjects with and without diagnosed OSA. In free-living conditions, Arms was 2.43 brpm and 95% LoA were −5.00 to 4.47 brpm (mean bias −0.27 brpm).
Conclusion We showed that the Corsano Cardiowatch 287 using PPG technology can monitor continuous RR and HR with high accuracy in healthy subjects as well as in patients diagnosed with OSA. We conclude that wearable devices like these enable new and more accessible ways to measure health, ultimately improving healthcare delivery. The trial was registered in the ISCRTN registry under reference ISRCTN13965929.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ISRCTN13965929
Funding Statement
This study was funded by Corsano Health
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Amsterdam Universitair Medische Centra waived ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
